Sarepta Therapeutics, Inc. (NASDAQ: SRPT): Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) and certain of the Company’s senior executives have been sued for violations of the federal securities laws. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317.
If you incurred losses on your investments in Sarepta, you are encouraged to submit your information.
Why Was Sarepta Sued for Securities Fraud?
Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta’s most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks.
In truth, Elevidys causes fatal acute liver failure in some patients.
The Stock Declines as the Truth Is Revealed
On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or over 27%, from $101.35 per share on March 17, 2025, to $73.54 per share on March 18, 2025. Nevertheless, on the same day, Sarepta assured investors that “the benefit-risk of ELEVIDYS remains positive.”
Next, on April 4, 2025, Sarepta revealed that European Union member country authorities requested that an independent data monitoring committee meet to review the circumstances of the death of the patient. As a result, Sarepta temporarily paused recruitment and dosing in some Elevidys clinical studies. On this news, the price of Sarepta stock fell $4.18 per share, or more than 7%, from $58.61 per share on April 3, 2025, to $54.43 per share on April 4, 2025.
Then, on June 15, 2025, Sarepta announced that a second patient treated with Elevidys had died from acute liver failure. The company further announced that because of the second death, it was suspending certain shipments of Elevidys and halted dosing in an ongoing clinical trial of the treatment. On this news, the price of Sarepta stock fell $15.24 per share, or more than 42%, from $36.18 per share on June 13, 2025, to $20.94 per share on June 16, 2025.
On June 24, 2025, the FDA issued a Safety Communication announcing that it was investigating the deaths and was evaluating the need for further regulatory action. On this news, the price of Sarepta stock fell $1.52 per share, more than 8%, from $18.98 per share on June 24, 2025, to $17.46 per share on June 25, 2025.
Most recently, on July 17, 2025, Sarepta revealed that a third patient treated with one of Sarepta’s investigational treatments related to Elevidys had died from acute liver failure in June 2025. On this news, the price of Sarepta stock fell more than 40% on July 18, 2025. On this news, the price of Sarepta stock fell more than 40% on July 18, 2025.
What Are My Rights?
If you purchased or otherwise acquired Sarepta securities, you may ask the court no later than August 25, 2025, which is the first business day after 60 days from the notice of pendency, to appoint you as Lead Plaintiff through counsel of your choice. To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.
Contact Us
If you incurred losses on your investments in Sarepta, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212.789.3619
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
